As filed with the Securities and Exchange Commission on June 27, 2008

February 22, 2021

Registration No. 333-


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

Washington, D.C. 20549
Form

FORM S-3

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933


CHINA BAK BATTERY,

CBAK ENERGY TECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)


Nevada
 
86-0442833
88-0442833
(State or other jurisdictionOther Jurisdiction of
incorporation
Incorporation or organization)
Organization)
 
(I.R.S. Employer

Identification No.)
Number)

BAK Industrial Park, No. 1 BAKMeigui Street

Kuichong Town, Longgang District
Shenzhen, 518119

Huayuankou Economic Zone

Dalian City, Liaoning Province, 116450

People’s Republic of China

(86-755) 8977-0093

(Address, including zip code, and telephone number,

including area code
of registrant’s principal executive offices)

Copies of Correspondence to:

CSC Services of Nevada, Inc.

2215 Renaissance Dr. Ste.

Las Vegas, NV, 89119

(866) 403 5272

(Name, address, and telephone number, including area
code, of agent for service)

Kevin (Qixiang) Sun, Esq.

Bevilacqua PLLC

1050 Connecticut Avenue, NW, Suite 500

Washington, DC 20036

202-869-0888


Thelen Reid Brown Raysman & Steiner LLP
701 8th St., N.W.
Washington, DC 20001
(202) 508-4000
(Name, address, including zip code, and telephone number,
including area code, of agent for service)

Copies of all communications, including communications sent to agent for service, should be sent to:
Louis A. Bevilacqua
Thelen Reid Brown Raysman & Steiner LLP
701 8th St., N.W.
Washington, DC 20001
(202) 508-4281

Approximate date of commencement of proposed sale to the public:From time to time on or after the effective date of this Registration Statement.Statement becomes effective.


If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. o


If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, please check the following box. þ


If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o


If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o


If delivery ofthis Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the prospectus is expected to be madeCommission pursuant to Rule 434, please462(e) under the Securities Act, check the following box. o


If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, please check the following box.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated FilerAccelerated Filer
Non-Accelerated FilerSmaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. o


CALCULATION OF REGISTRATION FEE


Title of Each Class of Securities to be Registered1)
Proposed Maximum
Aggregate Offering
Price (2)(3)
Amount of
Registration Fee (3)
Common Stock, $0.001 par value per share  
Warrants to Purchase Common Stock  
Total$60,000,000$2,358.00

Title of each class of
securities to be registered
 Amount to be Registered
(1)
  Proposed Maximum
Offering Price Per Unit
  Proposed Maximum
Aggregate Offering Price
  Amount of
Registration Fee (3)
 
Common Stock, par value $0.001 per share, underlying investor warrants (2)  4,469,988  $7.67  $34,284,807.96  $3,740.47 
Common Stock, par value $0.001 per share, underlying placement agent warrants (4)  446,999  $9.204  $4,114,178.80  $448.86 
Total  4,916,987      $38,398,986.76  $4,189.33 

(1)

Calculated pursuant to Rule 457(o) under the Securities Act. There is being registered hereunder an indeterminate number of shares of common stock and such indeterminate number of warrants to purchase shares of common stock of the registrant as may be sold from time to time by the registrant. Pursuant to Rule 416 under the Securities Act of 1933, as amended, or the sharesSecurities Act, the securities being registered hereunder include such indeterminate number of shares of common stock and such indeterminate number of warrants to purchase shares of common stocksecurities as may be issuable with respect to the sharessecurities being registered hereunder as a result of stock splits, stock dividends or similar transactions. The aggregate offering price for all shares of common stock and/or warrants that
(2)As described in greater detail in the registrant may sell from time to time pursuant toprospectus contained in this registration statement, will not exceed $60,000,000. Thethe shares of Common Stock to be offered for resale by selling stockholders include an aggregate amount of 4,469,988 shares of Common Stock underlying warrants issued to the registrant’s common stock and/or warrants registered hereunder that may be soldinvestors in “at the market” offerings for the account of the registrant is limited to that which is permissible underconnection with a private placement transaction on February 10, 2021.
(3)Calculated in accordance with Rule 415(a)(4)457(g) under the Securities Act.
(2)Estimated solely for the purposes of determining the registration fee pursuant to Rule 457(o) under the Securities Act.
(3)(4)PursuantAs described in greater detail in the prospectus contained in this registration statement, the shares of Common Stock to General Instruction II.D.be offered for resale by selling stockholder include an aggregate of Form S-3, the table does not specify by each class information as446,999 shares of Common Stock underlying a warrant issued to the proposed maximum aggregate offering price. Any securities registered hereunder may be sold separately orplacement agent in connection with other securities registered hereunder.a private placement transaction on February 10, 2021.

The Registrantregistrant hereby amends this Registration Statementregistration statement on such date or dates as may be necessary to delay its effective date until the Registrantregistrant shall file a further amendment which specifically states that this Registration Statementregistration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until this Registration Statementregistration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.





The information in this prospectus is not complete and may be changed. These securitiesThe selling stockholders named in this prospectus may not be soldsell these securities until the registration statement filed with the Securities and Exchange Commission is declared effective. This prospectus is not an offer to sell these securities and it isthe selling stockholders named in this prospectus are not soliciting an offeroffers to buy these securities in any statejurisdiction where the offer or sale is not permitted.

SUBJECT TO COMPLETION, DATED JUNE 27, 2008Subject to completion, dated February 22, 2021


PROSPECTUS



$60,000,000

CBAK ENERGY TECHNOLOGY, INC.

4,916,987 Shares of Common Stock

and
Common Stock Warrants

We

The selling stockholders named in this prospectus may use this prospectus to offer and resell from time to time up to 4,916,987 shares of our common stock, par value $0.001 per share (“Common Stock”), which are comprised of 4,469,988 shares of Common Stock (the “Series A-1 Warrant Shares”) issuable upon the exercise of Series A-1 Warrants (the “Series A-1 Warrants”), in each case issued in a private placement on February 10, 2021 (the “Private Placement”), pursuant to certain Securities Purchase Agreement by and among us and certain institutional investors (the “Investors”), dated as of February 8, 2021 (the “Securities Purchase Agreement”) and 446,999 shares of Common Stock (the “Placement Agent Warrant Shares”) issuable upon the exercise of the placement agent warrant (the “Placement Agent Warrant” and, together with Series A-1 Warrants, the “Warrants”) we issued to Mr. Jian Ke, the president of FT Global Capital, Inc. (“FT Global”), the placement agent in connection with the Securities Purchase Agreement, pursuant to a placement agency agreement between the Company and FT Global, dated February 8, 2021 (the “Placement Agency Agreement”).

The Series A-1 Warrants were issued in reliance upon the exemption from the registration requirements provided in Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and Regulation D (Rule 506(b)) promulgated thereunder. Each Investor represented that it was an “accredited investor” (as defined by Rule 501 under the Securities Act). We are registering the offer and resale of the Series A-1 Warrant Shares to satisfy a provision in certain registration rights agreement by and between the Company and each of the Investors, dated February 8, 2021 (the “Registration Rights Agreement”), pursuant to which we agreed to register the resale of the Series A-1 Warrant Shares within certain period of time.

In addition, the Placement Agent Warrant was issued to Mr. Jian Ke in reliance upon the exemption from the registration requirements provided in Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder.

We will not receive any of the proceeds from the sale of our Common Stock by the selling stockholders. However, we will receive proceeds from the exercise of the Warrants if the Warrants are exercised for cash. We intend to use those proceeds, if any, for general corporate purposes.

The selling stockholders named in this prospectus, may sell all or a portion of the shares of Common Stock held by them and offered hereby from time to time directly or through one or more underwriters, broker-dealers or agents. If the shares of Common Stock are sold through underwriters or broker-dealers, the selling stockholders will be responsible for underwriting discounts or commissions or agent’s commissions. The shares of Common Stock may be sold in one or more offerings common stock and/or warrants to purchase common stocktransactions at an aggregate public offering price of up to $60,000,000.

This prospectus provides you with a general description of the securities we may offer. Each time we offer securities, we will provide the specific terms of the offerings of our common stock and/or warrants to purchase common stock in supplements to this prospectus. The prospectus supplement also may add, update or change information contained in this prospectus. You should read this prospectus and any prospectus supplement, as well as the documents incorporated by reference or deemed to be incorporated by reference into this prospectus, carefully before you invest.

This prospectus may not be used to offer or sell our common stock and/or warrants to purchase common stock unless accompanied by a prospectus supplement. The information contained or incorporated in this prospectus or in any prospectus supplement is accurate only as of the date of this prospectus, or such prospectus supplement, as applicable, regardless offixed prices, at prevailing market prices at the time of deliverythe sale, at varying prices determined at the time of sale or at negotiated prices.

We will bear all costs, expenses and fees in connection with the registration of the shares of Common Stock offered hereby. For additional information on the methods of sale that may be used by the selling stockholders, see “Plan of Distribution” beginning on page 11 of this prospectus or any sale of our common stock.

prospectus.

Our common stock is quotedCommon Stock trades on the Nasdaq GlobalNASDAQ Capital Market under the symbol “CBAK.“CBAT.” The last reported sale price of our common stockCommon Stock on The Nasdaq Globalthe NASDAQ Capital Market on June 26, 2008,February 19, 2021 was $4.92$8.28 per share.

Investing in our securities involves a high degree of risk. You should carefully consider the risk factors beginning on page 25 of this prospectus and set forth in the documents incorporated by reference herein before making any decision to invest in our common stock.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.




securities.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus or any prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus is June 27, 2008, 2021



Page
ABOUT THIS PROSPECTUS1
SUMMARY
FORWARD-LOOKING STATEMENTS1
CBAK ENERGY TECHNOLOGY, INC.2
RISK FACTORS
THE OFFERING4
AVAILABLE INFORMATION4
INCORPORATION BY REFERENCE4
FORWARD-LOOKING STATEMENTSRISK FACTORS5
USE OF PROCEEDS6
SELLING STOCKHOLDERS 
USE OF PROCEEDS7
SELLING STOCKHOLDERS8
PLAN OF DISTRIBUTION611
DESCRIPTION OF CAPITALCOMMON STOCK913
DESCRIPTION OF WARRANTS9
MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES12
LEGAL MATTERS15
EXPERTS15
INDEMNIFICATION16
EXPERTS16
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE16
WHERE YOU CAN FIND MORE INFORMATION17

i


As permitted under the rules of the SEC, this prospectus incorporates by reference important information about China BAK Battery, Inc. that is contained in documents that we file with the SEC, but that are not attached to or delivered with this prospectus. You may obtain copies of these documents, without charge, from the website maintained by the SEC at www.sec.gov, as well as other sources. See “Available Information” for further information.

ABOUT THIS PROSPECTUS


This prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission or the (“SEC”) using a “shelf” registration process. UnderThe selling stockholders named in this shelf registration process, weprospectus may offerresell, from time to time, up to $60,000,000in one or more offerings, the shares of our common stock and/or warrants to purchase common stock. Each time we offer our common stock and/or warrants to purchase common stock, weCommon Stock offered by this prospectus. We will provide a prospectus supplement that describes the specific amounts, prices, and termsnot receive any of the common stock and/or warrantsproceeds from these sales of shares of Common Stock. The selling stockholders will bear all costs and fees related to purchase common stock we offer. The prospectus supplement(s) also may add, update, or change information containedunderwriting discounts, selling commissions, transfer taxes and fees, if any. We will bear the expenses incurred in connection with the registration of the shares of Common Stock covered by this prospectus.Please read carefully both this prospectus and any prospectus supplement together with additional information described below under “Where You Can Find More Information” and “Information Incorporated by Reference.”


You should rely only on the information contained or incorporated by reference in this prospectus or aany applicable prospectus supplement. We have not, and the selling stockholders have not, authorized anyoneany other person to provide you with different or additional information. If anyone provides you with different or inconsistentadditional information, you should not rely on it. This prospectus is neithernot an offer to sell, nor a solicitation ofare the selling stockholders seeking an offer to buy, any securities and it is not soliciting an offer to buy our securitiesthe shares of Common Stock offered by this prospectus in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearingcontained in this prospectus or in any applicable prospectus supplement as well as information we have previously filed with the SEC and incorporated by reference, is accurate only as of the date on the front cover thereof or the date of those documents only.the document incorporated by reference, regardless of the time of delivery of this prospectus or any applicable prospectus supplement or any sales of the shares of Common Stock offered hereby or thereby. Our business, financial condition, results of operations and prospectusprospects may have changed since those dates. that date.

Unless the context otherwise requires, the terms “we,” “our,” “us,” “our company,” and the “Company” in this prospectus each refer to CBAK Energy Technology, Inc. and its consolidated subsidiaries.

FORWARD-LOOKING STATEMENTS

This prospectus contains or incorporates forward-looking statements within the meaning of section 27A of the Securities Act and section 21E of the Exchange Act of 1934, as amended, or the Exchange Act. These forward-looking statements are management’s beliefs and assumptions. In addition, other written or oral statements that constitute forward-looking statements are based on current expectations, estimates and projections about the industry and markets in which we operate and statements may be made by or on our behalf. Words such as “should,” “could,” “may,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions that are difficult to predict. There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements.

We describe material risks, uncertainties and assumptions that could affect our business, including our financial condition and results of operations, in the “Risk Factors” section and may update our descriptions of such risks, uncertainties and assumptions in any prospectus supplement. We base our forward-looking statements on our management’s beliefs and assumptions based on information available to our management at the time the statements are made. We caution you that actual outcomes and results may differ materially from what is expressed, implied or forecast by our forward-looking statements. Accordingly, you should be usedcareful about relying on any forward-looking statements. Reference is made in particular to consummate a saleforward-looking statements regarding growth strategies, financial results, product and service development, competitive strengths, intellectual property rights, litigation, mergers and acquisitions, market acceptance or continued acceptance of our products, accounting estimates, financing activities, ongoing contractual obligations and sales efforts. Except as required under the federal securities unless it is accompaniedlaws, the rules and regulations of the SEC, stock exchange rules, and other applicable laws, regulations and rules, we do not have any intention or obligation to update publicly any forward-looking statements after the distribution of this prospectus, whether as a result of new information, future events, changes in assumptions, or otherwise.

1

CBAK ENERGY TECHNOLOGY, INC.

The information contained in or incorporated by areference into this prospectus supplement.

1

SUMMARY

This summary highlightssummarizes certain information about us and the common stock and/or warrants being offered by this prospectus. This summary is not complete andour company. It may not contain all of the information that is important to you. To understand this offering fully, you should consider prior to investing in our common stock and/or warrants. You shouldread carefully read the entire document,prospectus and the other information incorporated by reference into this prospectus.

Our Business

We are a manufacturer of new energy high power lithium batteries that are mainly used in light electric vehicles, electric vehicles, electric tools, energy storage, uninterruptible power supply (UPS) and other high-power applications.

We currently conduct our business through various operating subsidiaries located in China. We acquired most of our operating assets, including our customers, employees, patents and technologies from our former subsidiary BAK International (Tianjin) Ltd. We acquired these assets in exchange for a reduction in accounts receivable from our former subsidiaries that were disposed of in June 2014.

We generated revenues of $22.2 million and $24.4 million for the fiscal years ended December 31, 2019 and 2018, respectively, and revenues of $22.1 million and $17.5 million for the nine months ended September 30, 2020 and 2019, respectively. We had a net loss of $10.9 million and $2.0 million for the fiscal years ended December 31, 2019 and December 31, 2018, respectively, and had a net loss of $3.5 million and $6.9 million for the nine months ended September 30, 2020 and 2019, respectively. As of December 31, 2019, we had an accumulated deficit of $176.2 million and net assets of $13.7 million. As of September 30, 2020, we had an accumulated deficit of $179.7 million and net assets of $17.0 million. We had a working capital deficiency and accumulated deficit from recurring net losses and short-term debt obligations maturing in less than one year as of September 30, 2020.

Although the COVID-19 pandemic has caused disruptions to our operations, it has had limited adverse impacts on our operating results. Our revenue grew by $4.6 million, or 26% for the nine months ended September 30, 2020, compared to the same period of 2019, and our gross profit grew by $1.5 million, or 694% for the nine months ended September 30, 2020 compared to the same period of 2019. Meanwhile, our trade accounts and bills receivable increased by $10.9 million, or 136.8% as of September 30, 2020 compared to that as of December 31, 2019. 

We report financial and operational information in one segment. Management, including the risk factors, the financial statements and the documents incorporatedchief operating decision maker, reviews operating results solely by reference. References in this prospectus to: “China BAK,” “the Company,” “we,” “us” and “our” refer to China BAK Battery, Inc. and its consolidated subsidiaries.


Our Business

We are onemonthly revenue of the largest manufacturers of lithium-ion battery cells in the world, as measured by production output. We produce battery cells that are the principal component ofli-ion rechargeable batteries commonly used to power the following applications:

cellular phones—customer segments include original equipment manufacturing, or OEM, customers and replacement battery manufacturers;

notebook computers;

portable consumer electronics, such as digital cameras, portable media players, portable gaming devices and personal digital assistants, or PDAs; and

other applications, such as miner’s lamps.

We conduct all of our operations in China, in close proximity to China’s electronics manufacturing base and its rapidly growing market. Historically, we have primarily manufactured prismatic lithium-ion cells for the cellular phone replacement battery market and the OEM market. Our products are packed into batteries(but not by third-party battery pack manufacturers in accordance with the specifications of manufacturers of portable electronic applications. At the request of our customers that order prismatic battery packs, we also engage pack battery manufacturers to assemble our prismatic cells into batteries for a fee and then sell battery packs to these customers both for the replacement and OEM markets.
2

Our sub product type or geographic area).

Corporate Structure and Principal Executive Offices


Information

We were incorporated in the State of Nevada on October 4, 1999. On January 20, 2005, we completed a share exchange with the stockholders of BAK International, a Hong Kong company, pursuant to which we acquired 100% of BAK International. BAK International was a holding company that owned a 100% PRC operating subsidiary, Shenzhen BAK. On February 14, 2005, we merged with our wholly-owned subsidiary, China BAK Battery, Inc., which was incorporated on February 1, 2005, and changed our name from “Medina Coffee, Inc.” to our current name, “China BAK Battery, Inc.” We accounted for this share exchange as a reverse acquisition and succeeded to and are considered to be a continuation of Shenzhen BAK’s operations and financial statements. We conduct our current business through the following three wholly-owned operating subsidiaries in China that we own through BAK International:


Shenzhen BAK, located in Shenzhen, China, incorporated in August 2001, which focuses on the development and manufacture of three types of cells: prismatic cells, cylindrical cells and high-power lithium-phosphate cells;

BAK Electronics located in Shenzhen, China, incorporated in August 2005, which focuses on the development and manufacture of lithium polymer cells; and

BAK Tianjin, located in Tianjin, China, incorporated in December 2006, which focuses on the manufacture of advanced lithium-ion batteries for use in light electric vehicles and uninterruptible power supply units.
In addition, BAK Canada, a wholly-owned subsidiary of BAK International, was incorporated in Canada in December 2006 to advance our research and development of lithium-ion batteries, and in October 2007, Shenzhen BAK obtained the Approval Certificate of Overseas Investments of Chinese Enterprises to invest in a wholly-owned subsidiary in Germany, BAK Europe GmbH, which will focus on the sales and after-sales services of lithium-ion battery cells.

Our principal executive offices areoffice is located at BAK Industrial Park, No. 1 BAKMeigui Street, Kuichong Town, Longgang District, Shenzhen, 518119,Huayuankou Economic Zone, Dalian City, Liaoning Province, People’s Republic of China.China 116450. Our telephone number is (86-755) 8977-0093.

All inquiries should be directed to us at(+86)(411)3918-5985.

The following chart reflects our organizational structure as of the address and telephone number of our principal executive offices set forth above. Our website address is www.bak.com.cn. The information contained on our website does not form partdate of this prospectus.

2

3

*CBAK New Energy (Suzhou) Co., Ltd. (“CBAK Suzhou”) currently does not have any employees working locally. Since its lease expired in October 2019, CBAK Suzhou has stopped using the facilities located at its registered address. Some of its business has been transferred to our subsidiaries in Dalian and CBAK Suzhou’s remaining assets are temporarily stored in our facilities in Dalian. We plan to dissolve CBAK Suzhou in 2021.


3

THE OFFERING

Common Stock Offered by the Selling Stockholders

Up to 4,916,987 shares of Common Stock, which are comprised of 4,469,988 Series A-1 Warrant Shares and 446,999 Placement Agent Warrant Shares.
Selling StockholdersAll of the shares of Common Stock are being offered by the selling stockholders named herein. See “Selling Stockholders” on page 8 of this prospectus for more information on the selling stockholders.
Use of ProceedsWe will not receive any proceeds from the sale of the shares of our Common Stock in this offering. However, we will receive proceeds from the exercise of the Warrants if the Warrants are exercised for cash. We intend to use those proceeds, if any, for general corporate purposes. See “Use of Proceeds” beginning on page 7 of this prospectus for additional information.
Registration Rights

Under the terms of the Registration Rights Agreement, we have agreed to file this registration statement with respect to the registration of the resale by the selling stockholders of the Series A-1 Warrant Shares by the 30th calendar day after February 10, 2021 and cause the registration statement to be declared effective by the SEC by the earlier of (i) the 60th calendar day (or the 105th calendar day if the SEC reviews and has comments to this registration statement that would require the filing of a pre-effective amendment) after February 10, 2021 or (ii) the 3rd business day after we are notified by the SEC that such registration statement will not be reviewed or will not be subject to further review.

We are also required to keep the registration statement effective pursuant to Rule 415 under the Securities Act for resales by the selling stockholders on a delayed or continuous basis at then-prevailing market prices at all times until the earlier of (i) the date as of which all of the selling stockholders may sell all of the shares of Common Stock required to be covered by the registration statement without restriction pursuant to Rule 144 (including, without limitation, volume restrictions) and without the need for current public information required by Rule 144(c)(1) (or Rule 144(i)(2), if applicable) or (ii) the date on which the selling stockholders have sold all of the shares of Common Stock covered under the registration statement.

Plan of Distribution

The selling stockholders named in this prospectus, may sell all or a portion of the shares of Common Stock held by them and offered hereby from time to time directly or through one or more underwriters, broker-dealers or agents. If the shares of Common Stock are sold through underwriters or broker-dealers, the selling stockholders will be responsible for underwriting discounts or commissions or agent’s commissions. The shares of Common Stock may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale or at negotiated prices.

See “Plan of Distribution” beginning on page 11 of this prospectus for additional information on the methods of sale that may be used by the selling stockholders.

Risk FactorsInvesting in our Common Stock involves a high degree of risk. You should carefully read and consider the information beginning on page 5 of this prospectus set forth under the heading “Risk Factors” and all other information set forth in this prospectus, and the documents incorporated herein and therein by reference before deciding to invest in our Common Stock.
Nasdaq Capital Market symbolCBAT


RISK FACTORS

Any investment in our securities involves a high degree of risk. Before making an investment decision,you decide to invest in our securities, you should consider carefully consider the risks described underbelow as well as the risks described in the section captioned “Risk Factors” in the applicable prospectus supplement and in our most recent Annual Reportannual report on Form 10-K for the year ended December 31, 2019, and as updated by any updates in our Quarterly Reports on Form 10-Q, togetherdocument that we subsequently file with all of the other information appearingSEC that is incorporated by reference in this prospectus, ortogether with other information in this prospectus and the information and documents incorporated by reference intoin this prospectusprospectus. These risks and uncertainties described below and in these sections and documents are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. If any applicable prospectus supplement, in light of your particular investment objectives and financial circumstances. Oursuch risks actually occur, our business, operating results, prospects or financial condition or results of operations could be materially and adversely affected by any of these risks. Theaffected. This could cause the trading price of our securities couldCommon Stock to decline due to any of these risk factors, and you may lose all or any part of your investment.


AVAILABLE INFORMATION

We have filed with The risks discussed below also include forward-looking statements and our actual results may differ substantially from those discussed in these forward-looking statements. See “Forward-Looking Information.”

RISKS RELATED TO THIS OFFERING

If the SECCOVID-19 pandemic is not effectively controlled in a registration statement on Form S-3 undershort period of time, our business operation and financial condition in the Securities Actlong-term may be materially and adversely affected as a result of any slowdown in economic growth, operation disruptions or other factors that registerswe cannot predict.

The spread of the common stock to be soldnovel coronavirus (“COVID-19”), which was declared a pandemic by the selling stockholders. This prospectus does not containWorld Health Organization in March 2020, has caused different countries and cities to mandate curfews, including “shelter-in-place” and closures of most non-essential businesses as well as other measures to mitigate the spread of the virus. All of our operating subsidiaries are located in China. All of our employees and substantially all of our customers and suppliers are also located in China. The pandemic caused disruptions to our operations during the information set forth infirst quarter of 2020 and our business and operations fully resumed during the registration statement andsecond quarter of 2020. However, the exhibits filed as partextent of the registration statement. For further informationlong-term adverse impact of COVID-19 on our business and operations is highly uncertain and depends on several factors, such as the duration, severity, and geographic spread of the pandemic, development of the testing and treatment and stimulus measures of the government, all of which are out of our control.

Given the uncertainty of the outbreak, the spread of COVID-19 may be prolonged and worsened, and we may be forced to scale back or even suspend our operations. As COVID-19 spreads outside China, the global economy is suffering a noticeable slowdown. As this outbreak persists, commercial activities throughout the world have been curtailed with respectdecreased consumer spending, business operation disruptions, interrupted supply chain, difficulties in travel and reduced workforces. The duration and intensity of disruptions resulting from the COVID-19 outbreak is uncertain. It is unclear as to uswhen the outbreak will be contained, and we also cannot predict if the impact will be short-lived or long-lasting. The extent to which outbreak impacts our common stock,long-term financial results will depend on its future developments. If the COVID-19 pandemic is not effectively controlled in a short period of time, our long-term business operation and financial condition may be materially and adversely affected as a result of any slowdown in economic growth, operation disruptions or other factors that we refer youcannot predict.

We will have broad discretion as to the registration statement and the exhibits filed as a partuse of the registration statement. Statements contained inproceeds from this prospectus concerningoffering, and we may not use the contents of any contract or any other document are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, we refer you to the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit.


In addition, we file annual, quarterly and current reports, prospectuses and other information with the SEC. You may read and copy any materials that we file with the SEC at the SEC’s public reference room at 100 F Street, N.E., Washington, D.C. Please call the SEC at 1-800-SEC-0330 for more information about the operation of the public reference rooms. The SEC also maintains an internet website, at http://www.sec.gov, that contains our filed reports, proxy and information statements and other information that we file electronically with the SEC. Additionally, we make these filings available, free of charge, on our website at www.bak.com.cn as soon as reasonably practicable after we electronically file such materials with, or furnish them to, the SEC. The information on our website, other than these filings, is not, and should not be, considered part of this prospectus and is not incorporated by reference into this document.

INCORPORATION BY REFERENCE

The SEC allows us to “incorporate by reference” in this prospectus the information in our documents that we file with the SEC, which means that we disclose important information to you by referring you to documents that we have previously filed with the SEC or documents that we will file with the SEC in the future. The information incorporated by reference is considered to be part of this prospectus, and information in documents that we file later with the SEC will automatically update and supersede information in this prospectus. We incorporate by reference into this prospectus the documents listed below and any future filings made by us with the SEC under Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, or the Securities Exchange Act, until the offering is completed:

our Annual Report on Form 10-K for the fiscal year ended September 30, 2007, filed with the SEC on December 19, 2007;

our Quarterly Report on Form 10-Q for the quarter ended December 31, 2007, filed with the SEC on February 6, 2008;

our Quarterly Report on Form 10-Q for the quarter ended March 31, 2008, filed with the SEC on May 12, 2008;

our Current Reports on Form 8-K, filed with the SEC on March 31, 2008, and June 3, 2008; and

the description of our common stock set forth in our registration statement on Form 8-A, filed on June 6, 2006, pursuant to Section 12(b) of the Securities Exchange Act, including any amendment or report updating such description.

Any statement contained in a document incorporated or deemed to be incorporated by reference in this prospectus is modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded does not, except as so modified or superseded, constitute a part of this prospectus.
4

You may request a copy of these filings, at no cost, by written or oral request made to us at the following address or telephone number:

BAK Industrial Park, No. 1 BAK Street
Kuichong Town, Longgang District
Shenzhen, 518119
People’s Republic of China
(86-755) 8977-0093
Attention: Corporate Secretary

If you request a copy of any or all of the documents incorporated by reference, we will send to you the copies you request. However,proceeds effectively.

While we will not send exhibits to the documents, unless the exhibits are specifically incorporated by reference in the documents.


FORWARD-LOOKING STATEMENTS

Certain statements contained in this prospectus orreceive any prospectus supplement and incorporated by reference into this prospectus or any prospectus supplement are “forward-looking statements” within the meaning of such term in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause actual financial or operating results, performances or achievements expressed or implied by such forward-looking statements not to occur or be realized. Forward-looking statements made in this Report generally are based on our best estimates of future results, performances or achievements, predicated upon current conditions and the most recent results of the companies involved and their respective industries. Forward-looking statements may be identified by the use of forward-looking terminology such as “may,” “will,” “could,” “should,” “project,” “expect,” “believe,” “estimate,” “anticipate,” “intend,” “continue,” “potential,” “opportunity” or similar terms, variations of those terms or the negative of those terms or other variations of those terms or comparable words or expressions. Potential risks and uncertainties include, among other things, such factors as (i) our future business development, results of operations and financial condition; (ii) our ability to fund our operations and manage our substantial short-term indebtedness; (iii) our ability to maintain or increase our market share in the competitive markets in which we do business; (iv) our limited operating history in developing, manufacturing and selling of lithium-based rechargeable battery cells; (v) our ability to keep up with rapidly changing technologies and evolving industry standards, including our ability to achieve technological advances; (vi) our ability to secure raw materials in the future and to manage the costs of raw materials or to secure alternative or substitute raw materials; (vii) uncertainties with respect to the PRC legal and regulatory environment; (viii) our ability to maintain cost leadership; and (ix) other risks identified in this prospectus, any prospectus supplement and in our reports filed with the SEC.

Additional disclosures regarding factors that could cause our results and performance to differ from historical or anticipated results or performance are discussed in this prospectus or any prospectus supplement and in the reports incorporated by reference into this prospectus or any prospectus supplement. You are urged to carefully review and consider the various disclosures made by us therein before making any investment decision. The forward-looking statement speak only as of the date made and we disclaim any obligation to provide updates, revisions or amendments to any forward-looking statements to reflect changes in our expectations or future events.
5

USE OF PROCEEDS

Unless specified otherwise in the applicable prospectus supplement, we expect to use the net proceeds we receive from the sale of the shares of common stock and/or warrantsCommon Stock offered by this prospectus andby the accompanying prospectus supplement for general corporate purposes, whichselling stockholders, we may include, among other things:

·
acquisitions;

·working capital;
·capital expenditures;

·research and development expenditures;

·investments; and

·
repayment of debt.

The precise amount and timingreceive cash proceeds from the cash exercise of the Warrants. In that case, we have considerable discretion in the application of the proceeds of this offering. You will not have the opportunity, as part of your investment decision, to assess whether the net proceeds are being used in a manner agreeable to you. You must rely on our judgment regarding the application of the net proceeds of this offering. The net proceeds may be used for corporate purposes that do not improve our profitability or increase the price of our shares of Common Stock. The net proceeds may also be placed in investments that do not produce income or that lose value. The failure to use such proceedsfunds by us effectively could have a material adverse effect on our business, financial condition, operating results and cash flow.


A large number of shares of Common Stock may be sold in the market following this offering, which may significantly depress the market price of our Common Stock.

The shares of Common Stock sold in the offering will dependbe freely tradable without restriction or further registration under the Securities Act. As a result, a substantial number of our shares of Common Stock may be sold in the public market following this offering. If there are significantly more Common Stock offered for sale than buyers are willing to purchase, then the market price of our Common Stock may decline to a market price at which buyers are willing to purchase the offered Common Stock and sellers remain willing to sell our Common Stock.

You may experience dilution to the extent that shares of our Common Stock are issued upon the exercise of outstanding warrants or other securities that we may issue in the future.

You may experience dilution to the extent that our funding requirementsCommon Stock are issued upon the exercise of our outstanding warrants, and if we issue additional equity securities, or there are any issuances and subsequent exercises of stock options issued in the future. On February 10, 2021, pursuant to the Securities Purchase Agreement, we issued to the Investors (i) in the Private Placement, the Series A-1 Warrants to purchase a total of 4,469,988 shares of Common Stock, at a per share exercise price of $7.67 and exercisable for 42 months from the date of issuance; (ii) in a registered direct offering, certain Series B warrants to purchase a total of 4,469,988 shares of Common Stock, at a per share exercise price of $7.83 and exercisable for 90 days from the date of issuance; and (iii) in the registered direct offering, certain Series A-2 warrants to purchase up to 2,234,992 shares of Common Stock, at a per share exercise price of $7.67 and exercisable for 45 months from the date of issuance. In December 2020, we issued to the same investors warrants to purchase an aggregate of 3,795,920 shares of Common Stock at an exercise price of $6.46 per share. These warrants are exercisable until 36 months after the date of issuance. The exercise prices of all of the above warrants are subject to full-ratchet anti-dilution adjustment in the case of future issuances or deemed issuances of shares of Common Stock below the warrants’ exercise price then in effect, as well as customary adjustment in case of stock splits, stock dividends, stock combinations and similar recapitalization transactions. In addition, we issued to Mr. Jian Ke placement agent warrants to purchase up to 379,592 shares of Common Stock at an exercise price of $6.475 per share in December 2020 and the availabilityPlacement Agent Warrant to purchase up to 446,999 shares of Common Stock at an exercise price of $9.204 per share in February 2021. These warrants also bear customary anti-dilution protections in the event of stock dividends or splits, business combination, sale of assets, similar recapitalization transactions, or other similar transactions.


USE OF PROCEEDS

All shares of our Common Stock offered by this prospectus are being registered for the accounts of the selling stockholders, and cost of other capital. Pendingwe will not receive any specific application, we may initially invest funds in short-term marketable securities or apply them to the reduction of short-term indebtedness. Additional information on the use of net proceeds from the sale of these shares of Common Stock. However, we will receive proceeds from the exercise of the Warrants if the Warrants are exercised for cash. We intend to use those proceeds, if any, for general corporate purposes.

We will pay all expenses of the registration of the shares of Common Stock, including, without limitation, SEC filing fees and expenses of compliance with state securities or “blue sky” laws. The selling stockholders will bear underwriting discounts, commissions, placement agent fees or other similar expenses payable with respect to their sales of shares of our Common Stock.

See “Plan of Distribution” elsewhere in this prospectus for more information.

7

SELLING STOCKHOLDERS

This prospectus covers an aggregate of up to 4,916,987 shares of our Common Stock that may be sold or disposed by the selling stockholders pursuant to the exercise of the outstanding Warrants, which we issued to the selling stockholders in the Private Placement as described below.

Private Placement of Warrants

On February 10, 2021, pursuant to the Securities Purchase Agreement, we issued and sold to the Investors Series A-1 Warrants to purchase up to an aggregate of 4,469,988 shares of Common Stock at an exercise price equal to $7.67 per share in the Private Placement.

The Series A-1 Warrants have a term of 42 months from the date of issuance. The exercise price of Series A-1 Warrants is subject to customary adjustment in case of stock splits, stock dividends, stock combinations and similar recapitalization transactions. In addition, the exercise price of Series A-1 Warrants is subject to full-ratchet anti-dilution adjustment in the case of future issuances or deemed issuances of shares of our Common Stock below the applicable exercise price of the Series A-1 Warrants then in effect. However, without shareholder approval, the Series A-1 Warrants’ exercise price should not be adjusted to be less than $7.67, which is the average closing price of our Common Stock for the five trading days immediately prior to February 8, 2021. If at any time of exercise, there is no effective registration statement under the Securities Act registering the resale of the shares of Common Stock underlying Series A-1 Warrants, the Series A-1 Warrants may also be exercised, in whole or in part, by means of a cashless exercise according to a formula set forth in the Series A-1 Warrants.

In connection with the Private Placement, we also issued to Jian Ke, president of FT Global, the Placement Agent Warrant to purchase up to 446,999 shares of Common Stock, at an exercise price of $9.204 per share. The Placement Agent Warrant has the same terms and conditions as Series A-1 Warrants, except that it is not exercisable until 6 months after the date of issuance and does not contain full-ratchet anti-dilution protections.

In connection with the Private Placement, we and the Investors entered into the Registration Rights Agreement, pursuant to which, we are required within 30 calendar days of February 10, 2021 to file with the SEC a registration statement to register for the resale of the shares of Common Stock underlying Series A-1 Warrants. We are complying this requirement by filing this registration statement. We also agreed to register the underlying shares of Common Stock of the Placement Agent Warrant in this registration statement.

Information About Selling Stockholders

The shares of Common Stock being offered by the selling stockholders are those issuable to the selling stockholders upon exercise of the Warrants. For additional information regarding the issuance of the Warrants, see “Private Placement of Warrants” above. We are registering the underlying shares of Common Stock of the Warrants in order to permit the selling stockholders to offer the shares for resale from time to time. Except for the ownership of the shares of Common Stock and warrants issued by us pursuant to the Securities Purchase Agreement and in connection with the registered direct offering on December 10, 2020 (the “December Offering”), the selling stockholders have not had any material relationship with us within the past three years. Mr. Jian Ke is President of FT Global, which acted as the placement agent in connection with the December Offering and the Placement Agency Agreement.

The table below is based on information supplied to us by the selling stockholders and lists the selling stockholders and other information regarding the beneficial ownership (as determined under Section 13(d) of the Exchange Act, and the rules and regulations thereunder) of the shares of Common Stock held by each of the selling stockholders. Generally, a person “beneficially owns” shares of our Common Stock as of a date if the person has or shares with others the right to vote those shares or to dispose of them on that date, or if the person has the right to acquire voting or disposition rights within 60 days of that date. The second column lists the number of shares of Common Stock beneficially owned by the selling stockholders, based on their respective ownership of shares of Common Stock and outstanding warrants of the Company, as of February 19, 2021, assuming exercise of the warrants held by each such selling stockholder on that date but taking account of any limitations on exercise set forth therein. See note 1 to the table below for more information of the limitations on warrant exercise.


The third column lists the shares of Common Stock being offered by this prospectus by the selling stockholders and does not take in account any limitations on exercise of the warrants set forth therein.

In accordance with the terms of the Registration Rights Agreement, this prospectus generally covers the resale of 100% of the maximum number of shares of Common Stock issued or issuable pursuant to the Warrants. While the fourth column assumes the sale of all of the shares of Common Stock offered by the selling stockholders pursuant to this prospectus, the selling stockholders may only sell some or none of their shares of Common Stock in this offering. See “Plan of Distribution” below.

The percentage of beneficial ownership after this offering in this table is based on 93,023,006 shares as of February 19, 2021, assuming the resale of all shares of Common Stock (received upon exercise of the Warrants) covered by this prospectus may be set forth inand assuming no exercise of any other warrants issued by the prospectus supplement relating to the specific offering.

Company.

 

Name of Selling Stockholder

 Number of Shares of Common Stock Owned Prior to Offering(1)  Maximum Number of Shares of Common Stock to be Sold Pursuant
to this
Prospectus(2)
  Number of Shares of Common Stock Owned After Offering(3)  Percentage of Outstanding Common Stock Owned Following Offering(3) 

Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B (4)

  3,742,722   1,117,497   2,625,225   2.74%
Sabby Volatility Warrant Master Fund, Ltd. (5)  3,742,722   1,117,497   2,625,225   2.74%
Hudson Bay Master Fund Ltd. (6)  3,742,722   1,117,497   2,625,225   2.74%
CVI Investments, Inc. (7)  3,742,722   1,117,497   2,625,225   2.74%
Jian Ke (8)  0   446,999   0   * 

*Indicates less than 1%.

(1)The terms of the warrants held by the selling stockholders include a blocker provision that restricts exercise to the extent the securities beneficially owned by the selling stockholders and their affiliates would represent beneficial ownership in excess of 4.99%, or 9.99%, if applicable, of our Common Stock outstanding immediately after giving effect to such exercise, subject to the holder’s option upon notice to us to increase or decrease this beneficial ownership limitation; provided that any increase of such beneficial limitation percentage shall only be effective upon 61 days’ prior notice to us and such increased beneficial ownership percentage shall not exceed 9.99% of our Common Stockholder (such limitation, a “Beneficial Ownership Limitation”). None of the selling stockholders would currently reach the threshold for a Beneficial Ownership Limitation, even if they exercised all of their warrants.

(2)Represents the total number of shares of Common Stock underlying the Warrants owned by each of the selling stockholders, assuming full exercise of the Warrants offered hereby without taking into account any Beneficial Ownership Limitation.

(3)The number of shares owned and the percentage of beneficial ownership after this offering set forth in these columns are based on 88,106,019 shares of Common Stock issued and outstanding as of February 19, 2021 and assumes full exercise of the Warrants that are exercisable by each selling stockholder with respect to such selling stockholder and the sale of all of the shares of Common Stock underlying such Warrants.

(4)Includes 1,117,497 shares of Common Stock issuable exercise of Warrants and 2,625,225 shares of our Common Stock issuable upon exercise of certain other warrants. Ayrton Capital LLC, the investment manager to Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B (“Alto”), has discretionary authority to vote and dispose of the shares held by Alto and may be deemed to be the beneficial owner of these shares. Waqas Khatri, in his capacity as Managing Member of Ayrton Capital LLC, may also be deemed to have investment discretion and voting power over the shares held by Alto. Ayrton Capital LLC and Mr. Khatri each disclaims any beneficial ownership of these shares. The address of Ayrton Capital LLC is 55 Post Rd West, 2nd Floor, Westport, CT 06880.


(5)Includes 1,117,497 shares of Common Stock issuable exercise of Warrants and 2,625,225 shares of our Common Stock issuable upon exercise of certain other warrants. Sabby Management, LLC, the investment manager of Sabby Volatility Warrant Master Fund, Ltd., and Hal Mintz, manager of Sabby Management, LLC, may be deemed to share voting and dispositive power with respect to these securities. Each of Sabby Management, LLC and Hal Mintz disclaims beneficial ownership over the securities listed except to the extent of their pecuniary interest therein. The principal business address of Sabby Volatility Warrant Master Fund, Ltd. is c/o Ogier Fiduciary Services (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman KY1-9007, Cayman Islands. The principal business address of Sabby Management, LLC and Hal Mintz is 10 Mountainview Road, Suite 205, Upper Saddle River, New Jersey 07458.

(6)Includes 1,117,497 shares of Common Stock issuable exercise of Warrants and 2,625,225 shares of our Common Stock issuable upon exercise of certain other warrants. Hudson Bay Capital Management LP, the investment manager of Hudson Bay Master Fund Ltd., has voting and investment power over these securities. Sander Gerber is the managing member of Hudson Bay Capital GP LLC, which is the general partner of Hudson Bay Capital Management LP. Each of Hudson Bay Master Fund Ltd. and Sander Gerber disclaims beneficial ownership over these securities. The address of Hudson Bay Master Fund Ltd. is c/o Hudson Bay Capital Management LP, 777 Third Ave, 30th Floor, New York, NY 10017.

(7)Includes 1,117,497 shares of Common Stock issuable exercise of Warrants and 2,625,225 shares of our Common Stock issuable upon exercise of certain other warrants. Heights Capital Management, Inc., the authorized agent of CVI Investments, Inc. ("CVI"), has discretionary authority to vote and dispose of the shares held by CVI and may be deemed to be the beneficial owner of these shares. Martin Kobinger, in his capacity as Investment Manager of Heights Capital Management, Inc., may also be deemed to have investment discretion and voting power over the shares held by CVI. Mr. Kobinger disclaims any such beneficial ownership of the shares. CVI is affiliated with one or more FINRA member, none of whom are currently expected to participate in the sale of shares of Common Stock purchased by CVI and offered pursuant to this prospectus. The address of CVI is c/o Heights Capital Management, Inc., 101 California Street, Suite 3250, San Francisco, CA 94111.

(8)The address of the principal business office of Jian Ke is 5 Concourse Parkway, Suite 3000, Atlanta, GA 30328. Mr. Ke is the president of FT Global and holder of certain warrants (including the Placement Agent Warrant) issued by us, which will not become exercisable until June 10, 2021. Accordingly, as none of the warrants held by Mr. Ke are exercisable within 60 days, Mr. Ke currently is not deemed to have beneficial ownership over the shares of Common Stock offered by him in this offering.

PLAN OF DISTRIBUTION


We are registering the shares of our Common Stock issuable upon exercise of the Warrants to permit the resale of these shares of Common Stock by the holders of the Warrants from time to time after the date of this prospectus. We will not receive any of the proceeds from the sale by the selling stockholders of these shares of Common Stock. We will bear all fees and expenses incident to our obligation to register these shares of our Common Stock.

The selling stockholders may sell all or a portion of the securities beingshares of Common Stock held by them and offered by us in this prospectus (a)hereby from time to time directly or through one or more underwriters, broker-dealers or agents. If the shares of Common Stock are sold through underwriters or dealers, (b) directly to purchasers, (c) through agentsbroker-dealers, the selling stockholders will be responsible for underwriting discounts or (d) through a combinationcommissions or agent’s commissions. The shares of any of these methods. We and our agents and underwritersCommon Stock may sell the securities being offered by us in this prospectus from time to timebe sold in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale or at negotiated prices. These sales may be effected in and outsidetransactions, which may involve crosses or block transactions, pursuant to one or more of the United States:


following methods:

·at a fixed priceon any national securities exchange or prices,quotation service on which the securities may be changed;

·at market prices prevailinglisted or quoted at the time of sale;

·at prices related to such prevailing market prices; orin the over-the-counter market;

·at negotiated prices.in transactions otherwise than on these exchanges or systems or in the over-the-counter market;
6


The applicable prospectus supplement will include the following information:

·
the termsthrough the writing or settlement of the offering;
options, whether such options are listed on an options exchange or otherwise;

·the names of any underwriters or agents;

·the purchase price of the securities from usordinary brokerage transactions and if the purchase price is not payable in U.S. dollars, the currency or composite currencytransactions in which the purchasebroker-dealer solicits purchasers;

block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;

purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

an exchange distribution in accordance with the rules of the applicable exchange;

privately negotiated transactions;

short sales made after the date this registration statement is declared effective by the SEC;

broker-dealers may agree with a selling security holder to sell a specified number of such shares at a stipulated price is payable;per share;

·the net proceeds to us from the salea combination of securities;any such methods of sale; and

·any delayed delivery arrangements;other method permitted pursuant to applicable law.

·any underwriting discounts, commissions and other items constituting underwriters’ compensation;

·any initial public offering price;

·any discounts or concessions allowed or reallowed or paid to dealers; and

·
any commissions paid to agents.

We may engage in at-the-market offerings.

We may solicit directly offers to purchase securities. We

The selling stockholders may also designate agents from time to time to solicit offers to purchase securities. Any agent that we designate, who may be deemed to be an “underwriter” as that term is defined insell shares of Common Stock under Rule 144 promulgated under the Securities Act, if available, rather than under this prospectus. In addition, the selling stockholders may then reselltransfer the shares of Common Stock by other means not described in this prospectus. If the selling stockholders effect such securitiestransactions by selling shares of Common Stock to the public at varying prices to be determined byor through underwriters, broker-dealers or agents, such agent at the time of resale.

7

If we use underwriters, to sell securities, we would enter into an underwriting agreement with the underwriters at the time of the sale to them. The names of the underwriters would be set forth in the prospectus supplement which would be used by them together with this prospectus to make resales of the securities to the public. In connection with the sale of the securities offered, the underwritersbroker-dealers or agents may be deemed to have received compensation from us in the form of underwriting discounts or commissions. Underwriters may also receive commissions from purchasers of the securities. Underwriters may also use dealers to sell securities. If this happens, the dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters and/selling stockholders or commissions from purchasers of the purchasersshares of Common Stock for whom they may act as agents. Underwriting compensation paid by usagent or to underwriters in connection with the offering of the securities offered in this prospectus, andwhom they may sell as principal (which discounts, concessions or commissions as to particular underwriters, broker-dealers or agents may be in excess of those customary in the types of transactions involved). In connection with sales of the shares of Common Stock or otherwise, the selling stockholders may enter into hedging transactions with broker-dealers, which may in turn engage in short sales of the shares of Common Stock in the course of hedging in positions they assume. The selling stockholders may also sell shares of Common Stock short and deliver shares of Common Stock covered by this prospectus to close out short positions and to return borrowed shares in connection with such short sales. The selling stockholders may also loan or pledge shares of Common Stock to broker-dealers that in turn may sell such shares.


The selling stockholders may pledge or grant a security interest in some or all of the Warrants or shares of Common Stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of Common Stock from time to time pursuant to this prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending, if necessary, the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders also may transfer and donate the shares of Common Stock in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.

To the extent required by the Securities Act and the rules and regulations thereunder, the selling stockholders and any broker-dealer participating in the distribution of the shares of Common Stock may be deemed to be “underwriters” within the meaning of the Securities Act, and any commission paid, or any discounts or concessions allowed by underwriters to, participating dealers, wouldany such broker-dealer may be deemed to be underwriting commissions or discounts under the Securities Act. At the time a particular offering of the shares of Common Stock is made, a prospectus supplement, if required, will be distributed, which will set forth the aggregate amount of shares of Common Stock being offered and the terms of the offering, including the name or names of any broker-dealers or agents, any discounts, commissions and other terms constituting compensation from the selling stockholders and any discounts, commissions or concessions allowed or re-allowed or paid to broker-dealers.

Under the securities laws of some states, the shares of Common Stock may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states the shares of Common Stock may not be sold unless such shares have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with.

There can be no assurance that any selling stockholder will sell any or all of the shares of Common Stock registered pursuant to the registration statement, of which this prospectus forms a part.

The selling stockholders and any other person participating in such distribution will be subject to applicable provisions of the Exchange Act, and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the shares of Common Stock by the selling stockholders and any other participating person. To the extent applicable, Regulation M may also restrict the ability of any person engaged in the applicable prospectus supplement.


Underwriters, dealers, agentsdistribution of the shares of Common Stock to engage in market-making activities with respect to the shares of Common Stock. All of the foregoing may affect the marketability of the shares of Common Stock and other personsthe ability of any person or entity to engage in market-making activities with respect to the shares of Common Stock.

We will pay all expenses of the registration of the shares of Common Stock pursuant to the registration rights agreement, estimated to be $44,189.33 in total, including, without limitation, SEC filing fees and expenses of compliance with state securities or “blue sky” laws; provided, however, a selling stockholder will pay all underwriting discounts and selling commissions, if any. We will indemnify the selling stockholders against liabilities, including some liabilities under the Securities Act in accordance with the Registration Rights Agreement or the selling stockholders will be entitled to contribution. We may be entitled, under agreements that may be entered into with us, to indemnificationindemnified by usthe selling stockholders against certain civil liabilities, including liabilities under the Securities Act orthat may arise from any written information furnished to contribution with respect to payments which they may be required to makeus by the selling stockholders specifically for use in respect of such liabilities.


Underwriters and agents may engage in transactions with, or perform services for, us in the ordinary course of business. If so indicated in the applicablethis prospectus, supplement, we will authorize underwriters, dealers, or other persons to solicit offers by certain institutions to purchase securities pursuant to contracts providing for payment and delivery on a future date or dates. The obligations of any purchaser under these contracts would be subject only to those conditions described in the applicable prospectus supplement, and the prospectus supplement would set forth the price to be paid for securities pursuant to those contracts and the commissions payable for solicitation of the contracts.

Any underwriter may engage in over-allotment, stabilizing and syndicate short covering transactions and penalty bids in accordance with Regulation Mthe related Registration Rights Agreement or we may be entitled to contribution.

Once sold under the registration statement, of which this prospectus forms a part, the Securities Exchange Act. Over-allotment involves sales in excessshares of the offering size, which creates a short position. Stabilizing transactions involve bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Syndicate short covering transactions involve purchases of securitiesCommon Stock will be freely tradable in the open market after the distribution has been completed in order to cover syndicate short positions. Penalty bids permit the underwriters to reclaim selling concessions from dealers when the securities originally sold by such dealers are purchased in covering transactions to cover syndicate short positions. These transactions may cause the pricehands of the securities sold in an offering to be higherpersons other than it would otherwise be. These transactions, if commenced, may be discontinued by the underwriters at any time.

our affiliates.


Our common stock currently is traded on the Nasdaq Global Market. Any shares of

DESCRIPTION OF COMMON STOCK

The following describes our common stock sold pursuantand summarizes the material provisions of our articles of incorporation and amendments thereto and amended and restated bylaws, which is based upon, and is qualified by reference to, our articles of incorporation and amendments thereto, amended and restated bylaws and the applicable provisions of Nevada law. This summary does not purport to be complete. You should read our articles of incorporation and amendments thereto and bylaws which are filed as exhibits to the registration statement of which this prospectus forms a prospectus supplement also will be traded onpart, for the Nasdaq Global Market or on an exchange on which our common stock offeredprovisions that are important to you.

Common Stock

The Company is then listed, subject (if applicable)authorized to official notice of issuance. We are not obligatedissue up to maintain our listing on the Nasdaq Global Market. Any underwriters to whom we sell500,000,000 shares of common stock for public offering and sale may make a market in the securities that they purchase, but the underwriters will not be obligated to do so and may discontinue any market making at any time without notice.


The anticipated date of delivery of the securities offered hereby will be set forth in the applicable prospectus supplement relating to each offering.

8

Common Stock,
Our authorized capital stock consists of 100,000,000 shares of our common stock, with a par value of $0.001 per share. The Common Stock may be issued from time to time for such consideration as may be fixed by the Board of Directors, provided that the consideration fixed is not less than par value. As of June 26, 2008, we had 53,227,387February 19, 2021, there were 88,106,019 shares of common stock outstanding, excluding the common stock issuable upon exercise of our outstanding warrantsCommon Stock issued and options. As of June 26, 2008, we had approximately 102 record holders of our capital stock. outstanding.

Voting Rights and No Preemptive Rights

Each outstanding share of common stockCommon Stock entitles the holder thereof to one vote per share on all matters coming before the stockholders for a vote. Our articles of incorporation do not permit cumulative voting for the election of directors, which means that the holders of more than 50% of such outstanding shares voting for the election of directors can elect all of the directors to be elected, if they so choose; in such event, the holders of the remaining shares will not be able to elect any of our directors. Likewise, our articles of incorporation do not vary the size of the vote necessary for the stockholders to act on various matters from the size of the vote required by Nevada law, which requiresmeans, unless a different vote is required by express provisions of Nevada law, an action by the stockholders on a matter other than the election of directors toshall be approved if the number of votes cast in favor of the action exceeds the number of votes cast in opposition to the action. The directors of a Nevada corporation are elected at the annual meeting of the stockholders by a plurality of the votes cast at the election. Stockholders do not have preemptive rights to purchase shares in any future issuance of our common stock.


Common Stock.

Dividends

The holders of shares of our common stockCommon Stock are entitled to dividends out of funds legally available when and as declared by our board of directors. Our board of directors has never declared a dividend or otherwise authorized any cash or other distribution with respect to the shares of our common stockCommon Stock and does not anticipate declaring a dividend in the foreseeable future. Should we decide in the future to pay dividends, as a holding company, our ability to do so and meet other obligations depends upon the receipt of dividends or other payments from our operating subsidiaries and other holdings and investments. In addition, our operating subsidiaries, from time to time, may be subject to restrictions on their ability to make distributions to us, including as a result of restrictive covenants in loan agreements, restrictions on the conversion of local currency into dollars or other hard currency and other regulatory restrictions.

Liquidation

In the event of our liquidation, dissolution or winding up, holders of our common stockCommon Stock are entitled to receive, ratably, the net assets available to stockholders after payment of all creditors. All of the issued and outstanding shares of our common stock are duly authorized, validly issued, fully paid and non-assessable. To the extent that additional shares of our common stock are issued, the relative interests of existing stockholders will be diluted.


Warrants

The following description, together with the additional information we may include in any applicable prospectus supplement, summarizes the material terms and provisions of the warrants that we may offer under this prospectus and the related warrant agreements and warrant certificates. While the terms summarized below will apply generally to any warrants that we may offer, we will describe the particular terms of any series of warrants in more detail in the applicable prospectus supplement. If we so indicate in the prospectus supplement, the terms of any warrants offered under that prospectus supplement may differ from the terms described below.

General

We may issue warrants for the purchase of our common stock in one or more series. We may issue warrants independently or together with common stock, and the warrants may be attached to or separate from such shares of common stock. We will evidence each series of warrants by warrant certificates that we will issue under a separate agreement. We will describe in the applicable prospectus supplement the terms of the series of warrants, including, but not limited to:

·the offering price and aggregate number of warrants offered;

·the currency for which the warrants may be purchased;

·if applicable, the date on and after which the warrants and the related securities will be separately transferable;
9

·the number of shares of common stock purchasable upon the exercise of one warrant and the price at which such shares of common stock may be purchased upon such exercise;

·the effect of any merger, consolidation, sale, or other disposition of our business on the warrant agreement and the warrants;

·the terms of any rights to redeem or call the warrants;

·any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;

·the dates on which the right to exercise the warrants will commence and expire;

·the manner in which the warrant agreement and warrants may be modified;

·federal income tax consequences of holding or exercising the warrants; and

·any other specific terms, preferences, rights or limitations of or restrictions on the warrants.

Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including the right to receive dividends, if any, or payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any.

Exercise of Warrants

Each warrant will entitle the holder to purchase shares of our common stock on the terms and conditions and at the exercise price that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to 5:00 P.M. New York, New York time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will terminate.

Holders of the warrants may exercise the warrants by delivering the warrant certificate representing the warrants to be exercised together with specified information, and paying the required amount in immediately available funds, as provided in the applicable prospectus supplement. We will set forth on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver upon exercise of the warrants.

Upon receipt of the required payment and the warrant certificate properly completed and duly executed at our corporate offices, we will issue and deliver the shares of common stock issuable upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised, then we will issue a new warrant certificate for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender shares of common stock as all or part of the exercise price for warrants.

Enforceability of Rights By Holders of Warrants

In the event we engage the services of a warrant agent, any such warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants.
10

Anti-takeover Effects of Our Articles of Incorporation and By-laws


Bylaws

Our articles of incorporation and by-lawsbylaws contain certain provisions that may have the effect of entrenching our existing board members, delaying, deferring or preventing a future takeover or change in control of the company unless such takeover or change in control is approved by the board of directors.


These provisions include:

Special Meetings of Stockholders — Our articles of incorporation provide that special meetings of the stockholders can only be called by our president or any other executive officer, or the board of directors, or any member thereof, the record holder or holders of at least 10% of all shares entitled to vote at the meeting, and our bylaws provide that a special meeting will be called by the president or secretary at the written request of our stockholders holding not less than 30% of all the shares issued, outstanding and entitled to vote.

Special Meetings of Shareholders — Our articles of incorporation provide that special meetings of the stockholders can only be called by our president, or the board of directors, or the president or secretary at the written request of our stockholders holding not less than 10% of all the issued and outstanding stock.

Advance Notice Procedures — Our by-laws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders. At an annual meeting, our stockholders elect a board of directors and transact such other business as may properly be brought before the meeting. By contrast, at a special meeting, our stockholders may transact only the business for the purposes specified in the notice of the meeting unless all of our stockholders entitled to vote are present at the special meeting and consent.

Contracts and Transactions with Interested Directors — We may enter into a contract or a transaction with an entity in which our directors have a financial interest only if (a) such relationship has been disclosed to our board of directors or the committee, and our board of directors or the committee in good faith authorizes the contract or the transaction by the affirmative vote of a majority of the disinterested directors; (b) such relationship has been disclosed to our stockholders, and our stockholders have approved in good faith the contract or the transaction; or (c) the contract or transaction was fair to us at the time it was entered into and is later duly authorized, approved or ratified by our board of directors, the committee or stockholders.

Amendment of By-laws — Our by-laws may be amended by our board of directors alone.

Authorized but Unissued Shares — Our board of directors may cause us to issue our authorized but unissued shares of common stock in the future without stockholders’ approval. These additional shares may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital, corporate acquisitions and employee benefit plans. The existence of authorized but unissued shares of common stock could render more difficult or discourage an attempt to obtain control of a majority of our common stock by means of a proxy contest, tender offer, merger or otherwise.

Advance Notice Procedures — At an annual meeting, our stockholders elect a board of directors and transact such other business as may properly be brought before the meeting. By contrast, at a special meeting, our stockholders may transact only the business for the purposes specified in the notice of the meeting unless all of our stockholders entitled to vote are present at the special meeting and consent.

Contracts and Transactions with Interested Directors — We may enter into a contract or a transaction with an entity in which our directors or officers have a financial or other interest as long as such relationship has been disclosed to, or is known by, our board of directors, or is otherwise fair to the Company at the time it is authorized or approved.

Amendment of Bylaws — Our Bylaws may be amended by our board of directors alone.

Authorized but Unissued Shares — Our board of directors may cause us to issue our authorized but unissued shares of Common Stock in the future without stockholders’ approval. These additional shares may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital, corporate acquisitions and employee benefit plans. The existence of authorized but unissued shares of Common Stock could render more difficult or discourage an attempt to obtain control of a majority of our Common Stock by means of a proxy contest, tender offer, merger or otherwise.

Anti-Takeover Effects of Nevada Law


Nevada Business Combination Statute

We are subject to the “business combination” provisions of Sections 78.411 to 78.444 of Nevada’s Combinations with Interested Stockholders statute.the Nevada Revised Statutes. In general, such provisions prohibit a Nevada corporation with at least 200 stockholders from engaging in various “combination” transactions with any interested stockholder:


·for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the transaction is approved by the board of directors prior to the date the interested stockholder obtained such status; or

·after the expiration of the three-year period, unless:

·the transaction is approved by the board of directors or a majority of the voting power held by disinterested stockholders, or

·if the consideration to be paid by the interested stockholder is at least equal to the highest of: (a) the highest price per share paid by the interested stockholder within the three years immediately preceding the date of the announcement of the combination or in the transaction in which it became an interested stockholder, whichever is higher, (b) the market value per share of common stock on the date of announcement of the combination and the date the interested stockholder acquired the shares, whichever is higher, or (c) for holders of preferred stock, the highest liquidation value of the preferred stock, if it is higher.
11

stockholder for a period of two years after the date of the transaction in which the person became an interested stockholder, unless the transaction is approved by the board of directors prior to the date the interested stockholder obtained such status or the combination is approved by the board of directors and thereafter is approved at a meeting of stockholders by the affirmative vote of stockholders representing at least 60% of the outstanding voting power held by disinterested stockholders, and extends beyond the expiration of the two-year period, unless (a) the combination was approved by the board of directors prior to the person becoming an interested stockholder; (b) the transaction by which the person first became an interested stockholder was approved by the board of directors before the person became an interested stockholder; (c) the combination is later approved by a majority of the voting power held by disinterested stockholders; or (d) if the consideration to be paid by the interested stockholder is at least equal to the highest of: (i) the highest price per share paid by the interested stockholder within the two years immediately preceding the date of the announcement of the combination or in the transaction in which it became an interested stockholder, whichever is higher, or (ii) the market value per share of common stock on the date of announcement of the combination and the date the interested stockholder acquired the shares, whichever is higher.

A “combination” is generally defined to include mergers or consolidations or any sale, lease, exchange, mortgage, pledge, transfer, or other disposition, in one transaction or a series of transactions, with an “interested stockholder” or any affiliate or associate of an interested stockholder having: (a) an aggregate market value equal to more than 5% or more of the aggregate market value of the assets of the corporation, (b) an aggregate market value equal to more than 5% or more of the aggregate market value of all outstanding voting shares of the corporation, orand (c) more than 10% or more of the earning power or net income of the corporation.


In general, an

An “interested stockholder” is generally defined to mean a person who, together with affiliates and associates, owns (orbeneficial owner of at least 10% of the outstanding voting power or an affiliate or associate of the corporation that has been a 10% beneficial owner within three years, did own) 10% or more of a corporation’s voting stock.the preceding 2 years. The statutestatutes could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts to acquire our company even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price.


Nevada Acquisition of Controlling Interest Statute

Nevada’s Acquisition of Controlling Interest statuteStatute (NRS Sections 78.378-78.3793) applies only to Nevada corporations with at least 200 stockholders, including at least 100 stockholders of record who are Nevada residents, and which conduct business directly or indirectly in Nevada.Nevada and whose articles of incorporation or bylaws in effect 10 days following the acquisition of a controlling interest by an acquiror do not prohibit its application. As of the date of this prospectus, we do not believe we have 100 stockholders of record who are residents of Nevada, although there can be no assurance that in the future the Acquisitionacquisition of Controlling Interest statutecontrolling interest statutes will not apply to us.


The

Nevada’s Acquisition of Controlling Interest statuteStatute, prohibits an acquiror, under certain circumstances, from voting its shares of a target corporation’s stock after crossing certain threshold ownership threshold percentages, unless the acquiror obtains the approval of the target corporation’s disinterested stockholders. The statute specifies three thresholds:thresholds that constitute a controlling interest: (a) at least one-fifth or more but less than one-third,one-third; (b) at least one-third but less than a majority,majority; and (c) a majority or more, of the outstanding voting power. Once an acquiror crosses one of these thresholds, shares which it acquired in the above thresholds, those shares in an offer or acquisition and acquiredtransaction exceeding the threshold (or within 90ninety days thereofpreceding the date thereof) become “control shares” and such Control Shares arewhich could be deprived of the right to vote until a majority of the disinterested stockholders restore that right.

A special stockholders meeting may be called at the right.  The Acquisitionrequest of Controlling Interest statute also providesthe acquiror to consider the voting rights of the acquiror’s shares. If the acquiror requests a special meeting and gives an undertaking to pay the expenses of said meeting, then the meeting must take place no earlier than 30 days (unless the acquiror requests that the meeting be held sooner) and no more than 50 days (unless the acquiror agrees to a later date) after the delivery by the acquiror to the corporation of an information statement which sets forth the range of voting power that the acquiror has acquired or proposes to acquire and certain other information concerning the acquiror and the proposed control share acquisition.

If no such request for a stockholders meeting is made, consideration of the voting rights of the acquiror’s shares must be taken at the next special or annual stockholders meeting. If the stockholders fail to restore voting rights to the acquiror, or if the acquiror fails to timely deliver an information statement to the corporation, then the corporation may, if so provided in its articles of incorporation or bylaws, call certain of the acquiror’s shares for redemption at the average price paid for the control shares are accordedby the acquiror.

In the event the stockholders restore full voting rights and the acquiring person has acquiredto a holder of control shares that owns a majority or more of allthe voting power,stock, then all other stockholders who do not vote in favor of authorizingrestoring voting rights to the control shares are entitled tomay demand payment for the fair value“fair value” of their shares as determined by a court in accordance with statutory procedures established for dissenters’ rights.


dissenters rights proceeding pursuant to Chapter 92A of the Nevada Revised Statutes.

Listing

Our Common Stock is listed on Nasdaq Capital Market under the symbol “CBAT.”

Transfer Agent


Our transfer agent is Securities Transfer Corporation, 25912901 N Dallas Parkway, Suite 102, Frisco,380, Plano, Texas 75034.

75093.


MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES

The following summary describes material federal income tax consequences arising from the purchase, ownership and disposition of our common stock. This discussion does not cover all aspects of U.S. federal income taxation that may be relevant to each such holder due to the particular circumstances of such holder or address estate and gift tax consequences, state, local or other tax consequences or non-U.S. tax laws. This summary is based on the provisions of the Internal Revenue Code of 1986, as amended (the “Code”), final, temporary and proposed United States Treasury regulations promulgated thereunder, and the administrative and judicial interpretations thereof, all as in effect as of the date of this prospectus and all of which are subject to change, possibly with retroactive effect. In particular, this summary does not address the considerations that may be applicable to (a) particular classes of taxpayers, including financial institutions, insurance companies, small business investment companies, mutual funds, partnerships or other pass-through entities or investors in such entities, expatriates, broker-dealers and tax-exempt organizations, (b) holders with a “functional currency” other than the U.S. dollar or (c) holders of 10% or more of the total combined voting power of the Company’s shares. This summary deals only with the tax treatment of holders who own our common stock as “capital assets” as defined in Section 1221 of the Code.

THE SUMMARY OF U.S. FEDERAL INCOME TAX CONSIDERATIONS SET FORTH BELOW IS FOR GENERAL INFORMATION ONLY AND DOES NOT CONSTITUTE TAX ADVICE. ALL PROSPECTIVE PURCHASERS SHOULD CONSULT THEIR OWN TAX ADVISORS AS TO THE PARTICULAR TAX CONSEQUENCES TO THEM OF THE PURCHASE, OWNERSHIP, SALE OR OTHER DISPOSITION OF SECURITIES INCLUDING THE EFFECTS OF APPLICABLE STATE, LOCAL, NON-U.S. OR OTHER TAX LAWS, POSSIBLE CHANGES IN THE TAX LAWS AND THE POSSIBLE APPLICABILITY OF INCOME TAX TREATIES.
12

As used herein, the term “U.S. Holder” means a beneficial owner of our common stock that is for U.S. federal income tax purposes:

·a U.S. citizen or individual resident in the United States;

·a corporation, or other entity treated as a corporation created or organized under the laws of the United States or any political subdivision thereof;

·an estate the income of which is subject to U.S. federal income taxation regardless of its source; or

·a trust (i) if a U.S. court can exercise primary supervision over the administration of such trust and one or more U.S. fiduciaries have the authority to control all of the substantial interests of such trust or (ii) that has a valid election in effect under applicable U.S. Treasury regulations to be treated as a United States person.

Except as provided below in the discussion of estate tax, the term “Non-U.S. Holder” is a beneficial owner of our common stock that is, for U.S. federal income tax purposes, a nonresident alien individual or a corporation, trust or estate that is not a U.S. Holder.

If a partnership, including any entity treated as a partnership for U.S. federal income tax purposes, is a holder of our common stock, the tax treatment of a partner in the partnership will generally depend upon the status of the partner and the activities of the partnership. If you are a partnership, or a partner in such a partnership, you should consult your own tax advisor regarding the tax consequences of the purchase, ownership and disposition of our common stock.

Dividends

U.S. Holders. If distributions are paid on shares of our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Under current law, for tax years beginning before 2011, non-corporate taxpayers are eligible for a reduced rate of taxation on dividend income if certain holding period and other requirements are satisfied.

If a distribution exceeds our current and accumulated earnings and profits, it will constitute a return of capital that is applied against and reduces, but not below zero, a holder’s adjusted tax basis in our common stock. Any remainder will constitute gain as if from the sale of the common stock. See “- Dispositions.”

Non-U.S. Holders. Any dividends on our common stock paid to a Non-U.S. Holder generally will be subject to withholding of U.S. federal income tax at a 30% rate on the gross amount of the dividend or such lower rate as may be provided by an applicable income tax treaty. Dividends that are effectively connected with a Non-U.S. Holder’s conduct of a trade or business in the United States and, if a tax treaty applies, attributable to a permanent establishment (or, under certain treaties, a fixed base) in the United States, known as “U.S. trade or business income,” are generally not subject to the 30% withholding tax if the Non-U.S. Holder files the appropriate U.S. Internal Revenue Service form with the payor. However, such U.S. trade or business income, net of specified deductions and credits, generally is taxed at the same rates as applicable to U.S. persons. Any U.S. trade or business income received by a Non-U.S. Holder that is a corporation may also, under certain circumstances, be subject to an additional “branch profits tax” at a 30% rate or such lower rate as specified by an applicable income tax treaty.
A Non-U.S. Holder that claims the benefit of an applicable income tax treaty generally will be required to satisfy applicable certification and other requirements prior to the distribution date. Non-U.S. Holders should consult their tax advisors regarding their entitlement to benefits under a relevant income tax treaty.
13

A Non-U.S. Holder that is eligible for a reduced rate of U.S. federal withholding tax or other exclusion from withholding under an income tax treaty but that did not timely provide required certifications or other requirements, or that has received a distribution subject to withholding in excess of the amount properly treated as a dividend, may obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim for refund with the U.S. Internal Revenue Service.

Dispositions

U.S. Holders. A U.S. Holder will recognize gain or loss for U.S. federal income tax purposes upon the sale or other disposition of our common stock in an amount equal to the difference between the amount realized and the U.S. Holder’s adjusted tax basis for such stock. Such gain or loss will be capital gain or loss and will be long-term capital gain or loss if the stock had been held for more than one year. If the U.S. Holder’s holding period on the date of the sale or exchange is one year or less, such gain or loss will be short-term capital gain or loss. However, if a U.S. Holder has received a dividend to which the special reduced rate of tax, discussed above, applies, and which exceeds 10% of the U.S. Holder’s basis for the stock (taking into account certain rules that aggregate dividends for this purpose), any loss on sale or other disposition generally will be a long-term capital loss to the extent of that dividend, regardless of the U.S. Holder’s actual holding period. Under current law, for tax years beginning before 2011, non-corporate taxpayers are eligible for preferential tax rates in respect of long term capital gains. Any capital loss realized upon sale, exchange or other disposition of our common stock is generally deductible only against capital gains and not against ordinary income, except that in the case of noncorporate taxpayers, a capital loss may be deductible to the extent of capital gains plus ordinary income of up to $3,000.

A U.S. Holder’s tax basis for its shares of our common stock will generally be the purchase price paid therefor by such U.S. Holder (reduced by amounts of any distributions, in excess of earnings and profits of the Company, received by such U.S. Holder). The holding period of each share of our common stock owned by a U.S. Holder will commence on the day following the date of the U.S. Holder’s purchase of such share and will include the day on which the share is sold by such U.S. Holder.

Non-U.S. Holders. A Non-U.S. Holder generally will not be subject to U.S. federal income tax (or withholding thereof) on gain recognized on a disposition of our common stock unless:

·the gain is U.S. trade or business income, in which case such gain generally will be taxed in the same manner as gains of U.S. persons, and such gains may also be subject to the branch profits tax in the case of a corporate Non-U.S. Holder;

·the Non-U.S. Holder is an individual who is present in the United States for more than 182 days in the taxable year of the disposition and who meets certain other requirements, in which case such holder generally will be subject to U.S. federal income tax at a rate of 30% (or a reduced rate under an applicable treaty) on the amount by which capital gains allocable to U.S. sources (including gains from the sale, exchange, retirement or other disposition of the common stock) exceed capital losses allocable to U.S. sources; or

·we are or have been a “U.S. real property holding corporation” for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the Non-U.S. Holder held our common stock (the “applicable period”).

Generally, a corporation is a “U.S. real property holding corporation” if the fair market value of its “U.S. real property interests” equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business. The tax relating to stock in a “U.S. real property holding corporation” generally will not apply to a Non-U.S. Holder whose holdings, actual or constructive, at all times during the applicable period, constituted 5% or less of our common stock, provided that our common stock was regularly traded on an established securities market. We believe we have never been, are not currently and are not likely to become a U.S. real property holding corporation for U.S. federal income tax purposes in the future.

Information Reporting and Backup Withholding

We must report annually to the U.S. Internal Revenue Service and to each holder the amount of dividends paid to that holder and the tax withheld with respect to those dividends. Copies of the information returns reporting those dividends and the amount of tax withheld may also be made available to the tax authorities in the country in which a Non-U.S. Holder is a resident under the provisions of an applicable income tax treaty.
14

Backup withholding may apply to payments of dividends paid by us. If you are a U.S. Holder, backup withholding will apply if you fail to provide an accurate taxpayer identification number or certification of exempt status or fail to report all interest and dividends required to be shown on your federal income tax returns. Certain U.S. Holders (including, among others, corporations) are not subject to backup withholding.

If you are a Non-U.S. Holder, backup withholding will apply to dividend payments if you fail to provide us with the required certification that you are not a U.S. person.

Payments of the proceeds from a disposition (including a redemption) effected outside the United States by or through a non-U.S. broker generally will not be subject to information reporting or backup withholding. However, information reporting, but generally not backup withholding, will apply to such a payment if the broker has certain connections with the United States unless the broker has documentary evidence in its records that the beneficial owner of the disposed stock is a Non-U.S. Holder and either specified conditions are met or an exemption is otherwise established. Backup withholding and information reporting will apply to dispositions made by or through a U.S. office of any broker (U.S. or foreign).

Backup withholding is not an additional tax. Any amounts withheld from a payment to you that result in an overpayment of taxes generally will be refunded, or credited against your U.S. federal income tax liability, if any, provided that the required information is timely furnished to the U.S. Internal Revenue Service.

Holders should consult their own tax advisors regarding application of backup withholding in their particular circumstance and the availability of, and procedure for obtaining, an exemption from backup withholding under current U.S. Treasury regulations.

LEGAL MATTERS


Thelen Reid Brown Raysman & Steiner LLP will issue a legal opinion as to the

The validity of the issuance of the securities offered under this prospectus.


hereby will be passed upon for us by Sherman & Howard L.L.C.

EXPERTS


The consolidated financial statements as of September 30, 2007, andCBAK Energy Technology, Inc. for the yearyears ended September 30, 2007,December 31, 2019 and management’s assessment of the effectiveness of internal control over financial reporting as of September 30, 2007 (which is included in Management’s Report on Internal Control Over Financial Reporting)2018, incorporated by reference in this prospectus by reference toand the Annual Report on Form 10-K forregistration statement of which the year ended September 30, 2007,prospectus is a part, have been so incorporated in reliance onaudited by the reports of PKF, independent registered public accounting firms,firm Centurion ZD CPA & Co., as set forth in its report thereon, incorporated by reference elsewhere herein, and are included herein in reliance upon such report given on the authority of said firm as experts in auditing and accounting.


The consolidated financial statements of China BAK Battery, Inc. as of September 30, 2006, and for each of the years in the two-year period ended September 30, 2006, have been incorporated herein by reference in reliance upon the report of KPMG, independent registered public accounting firm, dated December 8, 2006, and upon the authority of saidsuch firm as experts in accounting and auditing.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE

The reportSEC allows us to “incorporate by reference” the information we file with them into this prospectus. This means that we can disclose important information about us and our financial condition to you by referring you to another document filed separately with the SEC instead of KPMG dated December 8, 2006, coveringhaving to repeat the consolidated financial statements asinformation in this prospectus. The information incorporated by reference is considered to be part of September 30, 2006,this prospectus and for eachlater information that we file with the SEC will automatically update and supersede this information. We incorporate by reference the documents listed below and any future filings made with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the yearsExchange Act, except for information “furnished” under Items 2.02, 7.01 or 9.01 on Form 8-K or other information “furnished” to the SEC which is not deemed filed and not incorporated in this prospectus, after the date hereof but before the completion or termination of this offering:

Our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed on May 14, 2020;

Our Quarterly Reports on Form 10-Q filed on July 2, 2020, August 14, 2020 and November 16, 2020;

Our Current Reports on Form 8-K filed on May 15, 2020, June 12, 2020, June 16, 2020, July 10, 2020, July 14, 2020, August 4, 2020, October 16, 2020, November 17, 2020, December 9, 2020, December 23, 2020, January 22, 2021andFebruary 9, 2021 (in each case, except for information furnished rather than filed);

Our Definitive Proxy Statement on Schedule 14A and Definitive Additional Materials on Schedule 14A filed on October 29, 2020;

The description of our Common Stock contained in our registration statement on Form 8-A filed on June 6, 2006 pursuant to Section 12(b) of the Exchange Act, including any amendment or reports filed hereafter for the purpose of updating such description; and

Any statement contained in a document that we incorporate by reference herein will be modified or superseded for all purposes to the extent that a statement contained in this prospectus (or in any other document that is subsequently filed with the SEC and incorporated by reference herein prior to the termination of this offering) modifies or is contrary to that previous statement. Any statement so modified or superseded will not be deemed a part of this prospectus except as so modified or superseded.

We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated by reference into such documents. Such request should be directed to: CBAK Energy Technology, Inc., BAK Industrial Park, Meigui Street, Huayuankou Economic Zone, Dalian City, Liaoning Province, People’s Republic of China 116450, and telephone number (+86)(411)3918-5985.


WHERE YOU CAN FIND MORE INFORMATION

We are subject to the informational requirements of the Exchange Act, and in accordance therewith file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address of the SEC’s website is www.sec.gov.

Additionally, we make these filings available, free of charge, on our website at http://www.cbak.com.cn as soon as reasonably practicable after we electronically file such materials with, or furnish them to, the SEC. The information on our website, other than these filings, is not, and should not be, considered part of this prospectus and is not incorporated by reference into this document.

This prospectus is part of a registration statement on Form S-3 that we filed with the SEC registering the securities that may be offered and sold hereunder. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the two-year period ended September 30, 2006, refersregistration statement, the exhibits filed therewith or the documents incorporated by reference therein. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a changepart of the registration statement (or incorporated by reference).

17

PART II

INFORMATION NOT REQUIRED IN THE PROSPECTUS

Item 14. Other Expenses of Issuance and Distribution

The following is a statement of the expenses to be incurred by us in connection with the methodregistration of accountingthe securities under this registration statement, all of which will be borne by us. All amounts shown are estimates except for stock-based compensation.

15



the SEC registration fee.

SEC registration fee $4,189.33 
Legal fees and expenses  25,000 
Accounting fees and expenses  5,000 
Transfer agent fees and expenses  5,000 
Miscellaneous  5,000 
Total $44,189.33 

Item 15. Indemnification of Directors and Officers.

Under Sections 78-7502, 78.751 and 78.752 of the Nevada Revised Statutes, we have broad powers to indemnify and insure our directors and officers against liabilities they may incur in their capacities as such. Our Amended and Restated Bylaws implement the indemnification and insurance provisions permitted by Chapter 78 of the Nevada Revised Statutes by providing that:


·We must indemnify our directors to the fullest extent permitted by Chapter 78 of the Nevada Revised Statutes and may, if and to the extent authorized by our board of directors, so indemnify our officers and any other person whom we have power to indemnify against liability, reasonable expense or other matter whatsoever.

·We may at the discretion of our board of directors to purchase and maintain insurance on behalf of our company and any person whom we have power to indemnify pursuant to law, our articles of incorporation, our bylaws or otherwise.

These indemnification provisions may be sufficiently broad to permit indemnification of our directors and officers for liabilities (including reimbursement of expenses incurred) arising under the Securities Act. We also have entered into indemnification agreements with our executive officers and directors and may provide indemnity insurance pursuant to which directors and officers are indemnified or insured against liability or loss under certain circumstances that may include liability, or related loss under the Securities Act and the Securities Exchange Act. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, or persons controlling the registrant pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.


The indemnity provisions may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions may also have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder’s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. We believe that these provisions, the indemnification agreements and the insurance are necessary to attract and retain talented and experienced directors and officers.

We have also agreed to use our best efforts to obtain an insurance policy coverage for our officers and directors with reputable insurers in the amount of such insurance coverage of at least $2,000,000.

II-1


At present, there is no pending litigation or proceeding involving any of our directors or officers where indemnification will be required or permitted. We are not aware of any threatened litigation or proceeding that might result in a claim for such indemnification.

16

PART II
INFORMATION NOT REQUIRED IN PROSPECTUS

Item 14.  Other Expenses of Issuance and Distribution


16. Exhibits.

The following table sets forth the expenses to be incurred in connection with the issuance and distribution of the securities registered under this Registration Statement, other than underwriting discounts and commissions.  All such expensesexhibits are estimates except for the SEC registration fee.  The following expenses will be borne solelyfiled herewith or incorporated herein by the registrant.


SEC registration fee $2,358 
Printing expenses  100,000 
Legal fees and expenses  175,000 
Accounting fees and expenses  105,000 
Transfer agent and registrar fees  10,000 
Miscellaneous expenses  10,000 
     
Total $402,358 

Item 15.  Indemnification of Directors and Officers

Under Sections 78.751 and 78.752 of the Nevada Revised Statutes, the registrant has broad powers to indemnify and insure its directors and officers against liabilities they may incur in their capacities as such. The registrant’s Amended and Restated Bylaws implement the indemnification and insurance provisions permitted by Chapter 78 of the Nevada Revised Statutes by providing that:


 ·The registrant may at the discretion
3.1Articles of its board of director purchase and maintain insurance on behalfIncorporation of the registrant (incorporated by reference to Exhibit 3.1 to the registrant’s Annual Report on Form 10-K filed on December 8, 2006)
3.2By-laws of the registrant (incorporated by reference to Exhibit 3.2 to the registrant’s Annual Report on Form 10-K filed on December 19, 2007)
3.3Certificate of Change Pursuant to NRS 78.209 filed by the Company on October 22, 2012 (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed on October 26, 2012)
3.4Certificate of Amendment to Articles of Incorporation filed by the Company on June 23, 2015 (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed on June 26, 2015)
4.1Specimen Common Stock Certificate of the registrant representing shares of Common Stock, par value $0.001 per share (incorporated by reference to Exhibit 4.1 to the registrant’s Form S-3 filed on November 23, 2020)
4.2Form of Investors Warrant (incorporated by reference to Exhibit 4.1 to the registrant’s Current Report on Form 8-K filed on February 9, 2021)
4.3Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.2 to the registrant’s Current Report on Form 8-K filed on February 9, 2021)
5.1*Opinion of Sherman & Howard L.L.C.
10.1Form of Securities Purchase Agreement by and among the Company and the Investors (incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed on February 9, 2021)
10.2Form of Registration Rights Agreement by and among the Company and the Investors (incorporated by reference to Exhibit 10.2 to the registrant’s Current Report on Form 8-K filed on February 9, 2021)
23.1*Consent of Centurion ZD CPA & Co., Independent Registered Public Accounting Firm.
23.2*Consent of Sherman & Howard L.L.C. (included in Exhibit 5.1).
24.1*Power of Attorney (included on signature page hereof).

*Filed herewith.

Item 17. Undertakings.

The undersigned registrant hereby undertakes:

(1)To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i)to include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

(ii)to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any person whom it has power to indemnifydeviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to law, its articlesRule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of incorporation, its bylawsRegistration Fee” table in the effective registration statement; and

II-2

(iii)to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or otherwise.any material change to such information in the registration statement,

These indemnification provisions may be sufficiently broad to permit indemnification of the registrant’s directors

provided, however, that subsections (i), (ii) and officers for liabilities (including reimbursement of expenses incurred) arising under the Securities Act.


The registrant also has entered into indemnification agreements with its executive officers and directors and provides indemnity insurance pursuant to which directors and officers are indemnified or insured against liability or loss under certain circumstances which may include liability, or related loss under the Securities Act and the Securities Exchange Act.
17

Item 16.Exhibits

The list of exhibits in the Exhibit Index to this prospectus is incorporated herein by reference.

Item 17.Undertakings

(a) The undersigned hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

Provided, however, that paragraphs (a)(1)(i), (a)(1)(ii), and (a)(1)(iii) of this sectionabove do not apply if the information required to be included in a post-effective amendment by those paragraphssubsections is contained in reports filed with or furnished to the CommissionSEC by the registrant pursuant to sectionSection 13 or sectionSection 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

(2) 

(2)That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:

(i) Each prospectus filed by the registrant pursuant to 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

(ii) each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.
18

(5) That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3)To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(4)That, for the purpose of determining liability under the Securities Act of 1933, as amended, to any purchaser:

(i)Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of this registration statement as of the date the filed prospectus was deemed part of and included in this registration statement.

(ii)Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of this registration statement in reliance on Rule 430B relating to an offer made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933, as amended, shall be deemed to be part of and included in this registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.

(5)That, for the purpose of determining liability of the registrant under the Securities Act of 1933, as amended, to any purchaser in the initial distribution of the securities:

The undersigned registrant undertakes that in a primaryan offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

(i)Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

(ii)Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

II-3

(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

(iv) 

(iii)The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

(iv)Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

(b) The undersigned registrant hereby undertakes that is an offer in the offering made by the undersigned registrant to the purchaser.

(6)That, for purposes of determining any liability under the Securities Act of 1933, as amended, each filing of the registrant’s annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934, as amended), that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(7)Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended, may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933, as amended, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

II-4

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, each filingthe registrant certifies that it has reasonable grounds to believe that it meets all of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered herein,requirements for filing on Form S-3 and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.


(c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

19

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this prospectusregistration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Shenzhen, People’s Republicthe city of Dalian, China, on June 27, 2008.
this 22nd day of February, 2021.

 CBAK ENERGY TECHNOLOGY, INC.
CHINA BAK BATTERY, INC.
  
 By:/s/ XiangqianYunfei Li
 

Xiangqian
Yunfei Li
Director, Chairman of the Board,
President and
Chief Executive Officer

POWER OF ATTORNEY


KNOW ALL PERSONSMEN BY THESE PRESENTS:


That the undersigned officersPRESENTS, that each person whose signature appears below constitutes and directors of China BAK Battery, Inc. do hereby constituteappoints Yunfei Li, his or her true and appoint Xiangqian Li and Tony Shen, and each of them, the lawful attorney and agent or attorneysattorneys-in-fact and agents, with full powers of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any or all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents full power and authority to do any and perform each and every act and thing requisite and necessary to be done, as fully for all actsintents and thingspurposes as he or she might or could do in person, hereby ratifying and to execute any andconfirming all instruments whichthat said attorneysattorneys-in-fact and agents, or either of them, determinetheir substitutes, may be necessary or advisable or required to enable China BAK Battery, Inc. to comply with the Securities Exchange Act of 1934, as amended, and any rules or regulations or requirements of the Securities and Exchange Commission in connection with this Registration Statement on Form S-3. Without limiting the generality of the foregoing power and authority, the powers granted include the power and authority to sign the names of the undersigned officers and directors in the capacities indicated below to this registration statement or amendments or supplements thereto (including registration statements filed pursuant to Rule 462(b)), and each of the undersigned hereby ratifies and confirms all that said attorneys and agents, or either of them, shalllawfully do or cause to be done by virtue hereof. This Power of Attorney may be signed in several counterparts.

IN WITNESS WHEREOF, each of the undersigned has executed this Power of Attorney as of the date indicated below.

*****

Pursuant to the requirements of the Securities Exchange Act of 1934,1933, this Registration Statement on Form S-3registration statement has been signed below by the following persons on behalf of the registrant in the capacities indicated on June 27, 2008.


indicated.

Signature
 
Title
Date
   
  
Director, /s/ Yunfei LiChairman of the Board, President and Chief Executive OfficerFebruary 22, 2021
/s/ XiangqianYunfei Li (Principal Executive Officer)
Name: Xiangqian Li
  
   
  Chief Financial Officer, Secretary and Treasurer
/s/ Tony ShenXiangyu PeiInterim Chief Financial OfficerFebruary 22, 2021
Xiangyu Pei (Principal Financial Officer and Principal Accounting Officer)
Name: Tony Shen
  
/s/ Guosheng WangDirectorFebruary 22, 2021
Guosheng Wang   
   
/s/ Huanyu MaoDirector, Chief Operating Officer and Chief Technical Officer
Name: Huanyu Mao
/s/ Richard B. GoodnerDirector
Name: Richard B. Goodner
  
/s/ J. Simon XueDirectorFebruary 22, 2021
J. Simon Xue   
   
/s/ Charlene Spoede BuddDirector
Name: Charlene Spoede Budd
  
/s/ Martha C. AgeeDirectorFebruary 22, 2021
Martha C. Agee   
   
/s/ Chunzhi ZhangJianjun He DirectorFebruary 22, 2021
Name: Chunzhi Zhang
Jianjun He
 

20

EXHIBIT INDEX

Exhibit Number
Description
   
1.1 Form of Underwriting Agreement.**
4.1 Form of Common Stock Warrant.**
5.1Opinion of Thelen Reid Brown Raysman & Steiner LLP.*
23.1Consent of PKF.*
23.2Consent of KPMG.*
23.3Consent of Thelen Reid Brown Raysman & Steiner LLP (included in Exhibit 5.1).
24.1Power of Attorney (included in signature page).

II-5

 
____________________
*Filed herewith.
**To be filed by amendment or incorporated by reference in connection with the offering of the securities.

21